SEC v. Hong (John) Wang; and Precision Clinical Consulting LLC, No. LR-26460, District of Massachusetts (Jan. 15, 2026) — Press Release
raw: Hong (John) Wang and Precision Clinical Consulting, LLC
Hong (John) Wang and Precision Clinical Consulting, LLC, No. LR-26460 (Jan. 15, 2026)
summary
Hong (John) Wang and his firm, Precision Clinical Consulting, LLC, were charged by the SEC for insider trading $489,739 in profits using nonpublic clinical trial data from C4 Therapeutics.
paragraph
Hong (John) Wang and Precision Clinical Consulting, LLC, face SEC charges for insider trading C4 Therapeutics, Inc. stock based on confidential biostatistical data. Wang allegedly realized $489,739 in profits by purchasing shares between November and December 2023 before positive clinical trial results were public. The SEC is seeking disgorgement, interest, and civil penalties for violations of Section 10(b) and Rule 10b-5.
narrative
The SEC charged Hong (John) Wang and his firm, Precision Clinical Consulting, LLC, with insider trading in C4 Therapeutics, Inc. stock. While performing biostatistical consulting for C4, Wang gained access to material nonpublic information regarding positive clinical trial results for a flagship drug. Between November 20, 2023, and December 12, 2023, Wang used four brokerage accounts to purchase shares, resulting in $489,739 in realized and unrealized profits. The SEC is seeking disgorgement, prejudgment interest, and civil penalties for violations of the Securities Exchange Act. Simultaneously, the U.S. Attorney’s Office for the District of Massachusetts filed parallel criminal charges against Wang. The investigation was a collaborative effort involving the SEC, the FBI, and FINRA.
Classified insider-trading(confidence 99%). EDGAR detection: forms 4/3/5/144· recall 81% / precision 19%. detection rule →
Parties
Securities and Exchange CommissionHong (John) WangPrecision Clinical Consulting LLC
Keywords
wangclinicalwang precisionprecisionhong johnjohn wangprecision clinicalclinical consultingsecurities exchangeclinical trialconsultingagainst wangsechongjohn
Exhibits & Attached Documents (1)
Extracted insights
Dollar amounts 1
- $490K $489,739 $100K–$1M
Entities 3
- person criminal charges against wang
- company hong (john) wang and precision clinical consulting, llc
- agency Securities and Exchange Commission
Triples 9
- Securities And Exchange Commission charged Hong (John) Wang and Precision Clinical Consulting, LLC
- Hong (John) Wang became aware of positive clinical trial results for C4’s flagship multiple myeloma and non-Hodgkin lymphoma drug
- Hong (John) Wang purchased C4 shares between November 20, 2023 and December 12, 2023
- Hong (John) Wang made $489,739 in realized and unrealized profits
- Securities And Exchange Commission charges Wang and Precision with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5
- Securities And Exchange Commission seeks disgorgement plus prejudgment interest against Wang and Precision
- Securities And Exchange Commission seeks permanent injunctive relief and civil penalties against Wang
- U.S. Attorney’s Office for the District of Massachusetts announced criminal charges against Wang
- Securities And Exchange Commission appreciates the assistance of U.S. Attorney’s Office for the District of Massachusetts, FBI, and Financial Industry Regulatory Authority
PDF (from attached: complaint)
Text layers
Extracted body text (2,475c)
U.S. SECURITIES AND EXCHANGE COMMISSIONLitigation Release No. 26460 / January 15, 2026Securities and Exchange Commission v. Hong (John) Wang and Precision Clinical Consulting, LLC, No. 26-civ-10140 (D. Mass. filed Jan. 14, 2026)SEC Charges Biopharmaceutical Company Consultant with Insider TradingOn January 14, 2026, the Securities and Exchange Commission charged New Jersey resident Hong (John) Wang and his company, Precision Clinical Consulting LLC, with insider trading in the stock of C4 Therapeutics, Inc., a clinical stage biopharmaceutical company headquartered in Watertown, Massachusetts.According to the SEC’s complaint, filed in the U.S. District Court of Massachusetts, Wang allegedly became aware of positive clinical trial results for C4’s flagship multiple myeloma and non-Hodgkin lymphoma drug while he was performing biostatistical consulting work for the company and had access to the drug’s clinical trial data. The complaint alleges that Wang’s consulting contract required him, among other things, to conduct biostatistical analysis on the clinical trial data related to this drug. According to the complaint, Wang allegedly purchased C4 shares between November 20, 2023 and December 12, 2023, while aware of material nonpublic information relating to the clinical trial. The complaint alleges that after C4 announced the positive results on December 12, 2023, Wang made $489,739 in realized and unrealized profits from his position. The complaint further alleges that Wang purchased C4 shares through four separate brokerage accounts, one of which is held in the name of Precision.The SEC’s complaint charges Wang and Precision with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and seeks disgorgement plus prejudgment interest thereon against Wang and Precision, and permanent injunctive relief and civil penalties against Wang.In a parallel action, on January 14, 2026, the U.S. Attorney’s Office for the District of Massachusetts announced criminal charges against Wang.The SEC’s investigation was conducted by William Conway, Melissa Coppola, Peter Mancuso, and Sandeep Satwalekar, and supervised by Thomas P. Smith, Jr., all in the New York Regional Office. The litigation will be led by Mr. Conway and Mr. Mancuso and supervised by Daniel Loss. The SEC appreciates the assistance of the U.S. Attorney’s Office for the District of Massachusetts, the FBI, and the Financial Industry Regulatory Authority.
OCR text (2,475c · html-text · 99% conf)
U.S. SECURITIES AND EXCHANGE COMMISSIONLitigation Release No. 26460 / January 15, 2026Securities and Exchange Commission v. Hong (John) Wang and Precision Clinical Consulting, LLC, No. 26-civ-10140 (D. Mass. filed Jan. 14, 2026)SEC Charges Biopharmaceutical Company Consultant with Insider TradingOn January 14, 2026, the Securities and Exchange Commission charged New Jersey resident Hong (John) Wang and his company, Precision Clinical Consulting LLC, with insider trading in the stock of C4 Therapeutics, Inc., a clinical stage biopharmaceutical company headquartered in Watertown, Massachusetts.According to the SEC’s complaint, filed in the U.S. District Court of Massachusetts, Wang allegedly became aware of positive clinical trial results for C4’s flagship multiple myeloma and non-Hodgkin lymphoma drug while he was performing biostatistical consulting work for the company and had access to the drug’s clinical trial data. The complaint alleges that Wang’s consulting contract required him, among other things, to conduct biostatistical analysis on the clinical trial data related to this drug. According to the complaint, Wang allegedly purchased C4 shares between November 20, 2023 and December 12, 2023, while aware of material nonpublic information relating to the clinical trial. The complaint alleges that after C4 announced the positive results on December 12, 2023, Wang made $489,739 in realized and unrealized profits from his position. The complaint further alleges that Wang purchased C4 shares through four separate brokerage accounts, one of which is held in the name of Precision.The SEC’s complaint charges Wang and Precision with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and seeks disgorgement plus prejudgment interest thereon against Wang and Precision, and permanent injunctive relief and civil penalties against Wang.In a parallel action, on January 14, 2026, the U.S. Attorney’s Office for the District of Massachusetts announced criminal charges against Wang.The SEC’s investigation was conducted by William Conway, Melissa Coppola, Peter Mancuso, and Sandeep Satwalekar, and supervised by Thomas P. Smith, Jr., all in the New York Regional Office. The litigation will be led by Mr. Conway and Mr. Mancuso and supervised by Daniel Loss. The SEC appreciates the assistance of the U.S. Attorney’s Office for the District of Massachusetts, the FBI, and the Financial Industry Regulatory Authority.